Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“Administration of DITC in post‐initiation phase also significantly reduced BrdU‐LI in bladder neoplasms and hyperplasia and cyclin D1‐positive cell ratios in urinary bladder carcinoma as well as dysplasia.”